ArticlePakistan journal of medical sciences2025
Landscape of somatic mutations in myeloproliferative neoplasm in Pakistani population.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to screen myeloproliferative neoplasm (MPN) patients for four known genetic variants to establish a diagnosis before treatment. Methods: This descriptive cross-sectional study was conducted at the Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, between January 2018 to January 2021. A total of 159 MPN patients were enrolled. Peripheral blood samples were screened for somatic variants in JAK2 V617F, JAK2 exon 12, CALR, and cMPL genes. The JAK2 V617F and cMPL mutations were analyzed using conventional PCR, while JAK2 Exon 12 and CALR mutations were analyzed using the fragment analysis technique. The gene scan data was interpreted by analyzing the electropherograms and the genotyping data sheet. The data were analyzed using the Statistical Package for Social Sciences (SPSS) version 25.0. Results: Out of a total of 159 MPN patients, 104 (65.4%) were males and 55 (34.6%) females. The median age of patients was 54 years (IQR: 38-64). 69 (43.4%) were diagnosed with primary myelofibrosis (PMF), 60 (37.7%) as polycythemia vera (PV), and 30 (18.9%) as essential thrombocytosis (ET). The frequency of the JAK2 V617F mutation in PV, ET, and PMF patients was 52.6%, 11.1%, and 37.3%, respectively. CALR mutation was observed only in 1 PMF and 5 (16.7%) ET patients. Additionally, cMPL mutation was not found among our patients. Conclusions: The four analyzed mutations are among the diagnostic criteria established by the World Health Organization, which enable a quick and reliable diagnosis of MPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.